Skip to main content

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Alzheimer's Disease

  • 2nd Edition - September 1, 2025
  • Editor: Adeboye Adejare
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 4 4 3 - 3 0 0 0 8 - 0
  • eBook ISBN:
    9 7 8 - 0 - 4 4 3 - 3 0 0 0 9 - 7

"Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, 2nd Edition" examines the drug discovery process for neurodegenerative diseases by… Read more

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Book bundle cover eBook and print

Institutional subscription on ScienceDirect

Request a sales quote
"Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, 2nd Edition" examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer’s Disease and illustrating the paradigm necessary to ensure future research and treatment success. The new edition of this book is updated with the most recent developments around the therapeutic strategies for drug discovery like amyloid hypothesis, tau, apo E, insulin, and others. It also includes a new chapter on drug delivery to the brain. The content covers diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. Pharmaceutical researchers will benefit from the updated coverage on therapeutic approaches to neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal disorder, Huntington’s diseases and many more. Patients and advocacy groups can also benefit from the overview of current treatment options and the scientific progress in the field.